Disposition of 30000 shares by Guyer William of Corcept Therapeutics at 19.26 subject to Rule 16b-3
CORT Stock | USD 55.31 0.87 1.60% |
Slightly above 66 percent of all Corcept Therapeutics' private investors are curious in acquiring. The analysis of overall sentiment of trading Corcept Therapeutics Incorporated stock suggests that a large number of investors are confidant at this time. Corcept Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Corcept Therapeutics' earnings reports, geopolitical events, and overall market trends.
Corcept |
Filed transaction by Corcept Therapeutics Incorporated Officer Chief Development Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Corcept Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Corcept Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Corcept Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Corcept Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Corcept Therapeutics Historical Investor Sentiment
Investor biases related to Corcept Therapeutics' public news can be used to forecast risks associated with an investment in Corcept. The trend in average sentiment can be used to explain how an investor holding Corcept can time the market purely based on public headlines and social activities around Corcept Therapeutics Incorporated. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Corcept Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Corcept Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Corcept Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Corcept Therapeutics.
Corcept Therapeutics Maximum Pain Price Across March 21st 2025 Option Contracts
Corcept Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Corcept Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Corcept Therapeutics' options.
Corcept Therapeutics Fundamental Analysis
We analyze Corcept Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Corcept Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Corcept Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Profit Margin
Profit Margin Comparative Analysis
Corcept Therapeutics is currently under evaluation in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Corcept Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Corcept Therapeutics stock to make a market-neutral strategy. Peer analysis of Corcept Therapeutics could also be used in its relative valuation, which is a method of valuing Corcept Therapeutics by comparing valuation metrics with similar companies.
Peers
Corcept Therapeutics Related Equities
MGTX | MeiraGTx Holdings | 5.56 | ||||
ANAB | AnaptysBio | 5.46 | ||||
SNSE | Sensei Biotherapeutics | 3.92 | ||||
KROS | Keros Therapeutics | 3.23 | ||||
NXTC | NextCure | 2.60 | ||||
AGIO | Agios Pharm | 1.89 | ||||
INSM | Insmed | 0.33 | ||||
ERAS | Erasca | 0.54 | ||||
HALO | Halozyme Therapeutics | 1.03 | ||||
NUVB | Nuvation Bio | 1.18 | ||||
EWTX | Edgewise Therapeutics | 1.72 | ||||
GLUE | Monte Rosa | 1.74 | ||||
RARE | Ultragenyx | 2.08 | ||||
IDYA | Ideaya Biosciences | 2.38 | ||||
CYTK | Cytokinetics | 2.66 | ||||
MLYS | Mineralys Therapeutics, | 2.74 | ||||
DYN | Dyne Therapeutics | 4.33 |
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.